JP4777570B2 - テザード・リガンド及び使用方法 - Google Patents

テザード・リガンド及び使用方法 Download PDF

Info

Publication number
JP4777570B2
JP4777570B2 JP2001547554A JP2001547554A JP4777570B2 JP 4777570 B2 JP4777570 B2 JP 4777570B2 JP 2001547554 A JP2001547554 A JP 2001547554A JP 2001547554 A JP2001547554 A JP 2001547554A JP 4777570 B2 JP4777570 B2 JP 4777570B2
Authority
JP
Japan
Prior art keywords
ligand
domain
receptor
cells
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001547554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003518138A5 (enExample
JP2003518138A (ja
Inventor
ジェイ スコール、トーマス
タルボット、デイル
ミアオ、ツェンファ
ウェイ、ツェング
Original Assignee
ケモセントリックス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケモセントリックス インコーポレーテッド filed Critical ケモセントリックス インコーポレーテッド
Publication of JP2003518138A publication Critical patent/JP2003518138A/ja
Publication of JP2003518138A5 publication Critical patent/JP2003518138A5/ja
Application granted granted Critical
Publication of JP4777570B2 publication Critical patent/JP4777570B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2001547554A 1999-12-20 2000-12-18 テザード・リガンド及び使用方法 Expired - Fee Related JP4777570B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17297999P 1999-12-20 1999-12-20
US60/172,979 1999-12-20
US18662600P 2000-03-03 2000-03-03
US60/186,626 2000-03-03
US09/721,908 2000-11-24
US09/721,908 US6699677B1 (en) 1999-12-20 2000-11-24 Tethered ligands and methods of use
PCT/US2000/034503 WO2001046698A2 (en) 1999-12-20 2000-12-18 Tethered ligands and methods of use

Publications (3)

Publication Number Publication Date
JP2003518138A JP2003518138A (ja) 2003-06-03
JP2003518138A5 JP2003518138A5 (enExample) 2008-02-28
JP4777570B2 true JP4777570B2 (ja) 2011-09-21

Family

ID=27390216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001547554A Expired - Fee Related JP4777570B2 (ja) 1999-12-20 2000-12-18 テザード・リガンド及び使用方法

Country Status (9)

Country Link
US (1) US6699677B1 (enExample)
EP (1) EP1247103B1 (enExample)
JP (1) JP4777570B2 (enExample)
AT (1) ATE405838T1 (enExample)
AU (1) AU2440001A (enExample)
CA (1) CA2390690C (enExample)
DE (1) DE60040019D1 (enExample)
ES (1) ES2311485T3 (enExample)
WO (1) WO2001046698A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998239B1 (en) * 1999-10-12 2006-02-14 Chemocentryx, Inc. Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine
USRE39849E1 (en) 1999-10-12 2007-09-18 Chemocentryx, Inc. Methods for identifying modulators of CCX CKR activity
US6780602B2 (en) * 2001-11-01 2004-08-24 Microbiosystems, Limited Partnership Taxonomic identification of pathogenic microorganisms and their toxic proteins
US7413866B2 (en) * 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US20060160076A1 (en) * 2002-06-10 2006-07-20 Meatabolex, Inc. Methods of treating and diagnosing diabetes with cx3cr1 modulators
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
US20040115634A1 (en) 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
US7981694B2 (en) * 2003-01-28 2011-07-19 The Regents Of The University Of California Solid phase isolation of proteins, nucleic acids and other macromolecules
GB0306428D0 (en) * 2003-03-20 2003-04-23 Oxagen Ltd Receptor proteins
EP1613737A4 (en) 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
EP1656092B1 (en) * 2003-08-12 2008-07-23 Philips Intellectual Property & Standards GmbH Closure device for a container
DK2211183T3 (da) * 2003-11-19 2013-05-13 Satoris Inc Fremgangsmåde til diagnosticering og overvågning af Alzheimer's sygdom
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
US7884052B2 (en) 2004-09-03 2011-02-08 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
EP1789792A2 (en) 2004-09-11 2007-05-30 Receptors LLC Combinatorial artificial receptors including peptide building blocks
US7585968B2 (en) 2005-03-28 2009-09-08 Isis Pharmaceuticals, Inc. Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
US20060258610A1 (en) 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
WO2007005715A2 (en) * 2005-07-01 2007-01-11 Inhibtex, Inc. Staphylococcal antibodies which cross-react with fungal antigens
CA2673085C (en) 2006-12-12 2013-10-15 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
WO2009124295A2 (en) * 2008-04-04 2009-10-08 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
US9163094B2 (en) 2011-09-27 2015-10-20 Massachusetts Institute Of Technology Light-activated fusion proteins and uses therefor
US9718887B2 (en) 2012-09-06 2017-08-01 Adelaide Research & Innovation Pty Ltd Methods and products for preventing and/or treating metastatic cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049557A1 (en) * 1997-04-28 1998-11-05 B-E Safe, Inc. Taxonomic identification of microorganisms, proteins and peptides involved in vertebrate disease states

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507602A (ja) 1993-02-19 1996-08-13 アリス・ファーマスーティカル・コーポレイション リガンドを構成しかつ提示するための薄膜ｈｐｍｐマトリックス系および方法
JPH07147987A (ja) 1993-05-28 1995-06-13 Wisconsin Alumni Res Found ユビキチン接合性酵素（ｅ２）融合タンパク質
US5763199A (en) 1994-09-29 1998-06-09 Mount Sinai School Of Medicine Of The City University Of New York Platelet blockade assay
US5817527A (en) 1995-11-06 1998-10-06 Chiron Diagnostics Corporation Conjugation of ligand to immobilized protein in organic solvent
EP0876487B1 (en) 1996-01-24 2008-03-12 Schering Corporation Mammalian cx3c chemokine genes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049557A1 (en) * 1997-04-28 1998-11-05 B-E Safe, Inc. Taxonomic identification of microorganisms, proteins and peptides involved in vertebrate disease states

Also Published As

Publication number Publication date
ATE405838T1 (de) 2008-09-15
CA2390690C (en) 2010-08-10
JP2003518138A (ja) 2003-06-03
ES2311485T3 (es) 2009-02-16
AU2440001A (en) 2001-07-03
CA2390690A1 (en) 2001-06-28
US6699677B1 (en) 2004-03-02
EP1247103B1 (en) 2008-08-20
EP1247103A2 (en) 2002-10-09
DE60040019D1 (de) 2008-10-02
WO2001046698A3 (en) 2002-02-21
WO2001046698A2 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
JP4777570B2 (ja) テザード・リガンド及び使用方法
Wilbanks et al. Expression cloning of the STRL33/BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines
Lean et al. CCL9/MIP‐1γ and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts
CA1328419C (en) Receptors for efficient determination of ligands and their antagonists or agonists
KR100271725B1 (ko) cDNA 라이브러리의 작제 방법 및 신규의 폴리펩티드와 그것을 암호하는 DNA
JP5973591B2 (ja) 改善された細胞表面発現を有するｇｐｃｒ
JP2002513588A (ja) 所望の生物学的特性を与えるクローンを発現ライブラリーから同定する新規方法
TW201245718A (en) Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity
JP2018500553A (ja) 患者試料における生物製剤の検出のための間接的均一移動度シフトアッセイ
Li et al. Development of a membrane-anchored ligand and receptor yeast two-hybrid system for ligand-receptor interaction identification
KR19990063834A (ko) 단형 케모킨 베타-8
CA2387018C (en) Chemokine receptor
JPH11243960A (ja) ヒトｃｃ型ケモカインエオタキシン３
JPWO2002036823A1 (ja) 核移行蛋白質をコードする遺伝子の検索法
US6998239B1 (en) Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine
US7348151B1 (en) Method for the cellular high-throughput-detection of nuclear receptor ligand interactions
CA2710760C (en) Cynomolgus toll-like receptor 3
US12455290B2 (en) Methods for detecting meteorin-β activity
JP7423250B2 (ja) 評価方法、スクリーニング方法および評価キット
Islam et al. Chemokine and chemokine receptor analysis
JPWO2006134960A1 (ja) 抗炎症剤のスクリーニング方法
JP2001103967A (ja) ブタ由来インターロイキン−１８に対するモノクローナル抗体
EP4469798A1 (en) High-throughput assay for cell migration, chemotaxis, and function
WO2004094638A1 (ja) 血管炎抗原ペプチドと血管炎診断方法
CN120025449A (zh) γ-氨基丁酸B型受体纳米抗体及其制备方法与应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110531

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110630

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4777570

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140708

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees